aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Moonwalk Biosciences, founded in San Francisco, California, is a pioneering genomic medicine startup focused on developing precision epigenetic therapeutics. The company's core mission is to revolutionize the way therapies are discovered and developed by providing a comprehensive view of the epigenome in health and disease. Utilizing advanced artificial intelligence, Moonwalk's profiling and engineering technology platform aims to reprogram cells to their healthy state, offering a novel approach to medical treatments.
Notable affiliated individuals and investors include leading experts in genomics and biotechnology, although specific names are not disclosed. Key achievements include being the first company to couple an epigenetic discovery platform with precise engineering, opening up new target spaces within the epigenome for complex diseases. Moonwalk Biosciences' impact lies in its innovative approach to precision medicine, potentially transforming therapeutic development and offering new hope for treating various health conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Epigenetic Therapeutics
Technology
AI, Machine Learning
Tags
Biotech, Healthtech
When was Moonwalk Biosciences founded?
Moonwalk Biosciences was founded in 2022.
When was Moonwalk Biosciences's last funding round?
Moonwalk Biosciences's most recent funding round was for $57M (USD) in January 2024.
How many employees does Moonwalk Biosciences have?
Moonwalk Biosciences has 5 employees as of Feb 5, 2024.
How much has Moonwalk Biosciences raised to-date?
As of July 05, 2023, Moonwalk Biosciences has raised a total of $57M (USD) since Jan 4, 2024.
Add Comparison
Total Raised to Date
$57M
USD
Last Update Jan 4, 2024
Last Deal Details
$57M
USD
Jan 4, 2024
Series A
Total Employees Over Time
5
As of Feb 2024
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts